Ok just listened to it. Honestly not really worth listening to.
They had a stock standard answer for biotechs. Saying very high risk and 99% fail. Just a general statement about Bio-techs in cancer space. It was obvious they have not looked at the company other than knowing it is cancer related and immunology related.
Seriously, you will glean more from reading Anns and looking at vid from Imugene.
DYOR and all that.
Media Thread, page-1167
-
- There are more pages in this discussion • 14,696 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.001(2.04%) |
Mkt cap ! $357.0M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $279.2K | 5.733M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 94 | 12992150 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 1795056 | 6 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |